CA Patent

CA3039735A1 — Combination containing sgc activators and mineralocorticoid receptor antagonists

Assigned to Bayer Pharma AG · Expires 2018-04-19 · 8y expired

What this patent protects

The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardiovascular diseases, renal and cardiorenal d…

USPTO Abstract

The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardiovascular diseases, renal and cardiorenal diseases, pulmonary and cardiopulmonary disease, and to treat and/or prevent fibrotic diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA3039735A1
Jurisdiction
CA
Classification
—
Expires
2018-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.